603939 益丰药房
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)8.11515.01314.89115.38315.739
总资产报酬率 ROA (%)3.6186.0575.8676.2526.626
投入资产回报率 ROIC (%)4.3217.1677.0107.6117.995

边际利润分析
销售毛利率 (%)40.29739.35640.12038.20939.529
营业利润率 (%)11.92610.0439.1599.0979.482
息税前利润/营业总收入 (%)12.35210.6359.7939.4029.968
净利润/营业总收入 (%)8.8137.4946.8696.9997.158

收益指标分析
经营活动净收益/利润总额(%)96.55893.79795.68496.763100.034
价值变动净收益/利润总额(%)3.9035.0784.9542.0800.366
营业外收支净额/利润总额(%)-0.3380.109-0.979-0.844-0.429

偿债能力分析
流动比率 (X)1.6021.4321.2591.0761.095
速动比率 (X)1.1821.0370.8990.7380.721
资产负债率 (%)49.82554.90859.27256.71756.652
带息债务/全部投入资本 (%)36.57442.52944.67039.31638.394
股东权益/带息债务 (%)154.407118.179101.354125.160129.685
股东权益/负债合计 (%)94.15977.18564.68671.62071.771
利息保障倍数 (X)26.48318.29113.55024.64218.913

营运能力分析
应收账款周转天数 (天)26.47730.09431.88431.73326.438
存货周转天数 (天)108.342111.339104.14195.72299.615